Anupam Rama
Stock Analyst at JP Morgan
(4.36)
# 345
Out of 5,143 analysts
308
Total ratings
48.62%
Success rate
20.26%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $177 → $176 | $128.38 | +37.09% | 21 | Feb 17, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $46 → $39 | $19.72 | +97.77% | 13 | Feb 5, 2026 | |
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $42.06 | +128.25% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $37.06 | +80.79% | 9 | Dec 19, 2025 | |
| VOR Vor Biopharma | Maintains: Overweight | $43 → $40 | $15.42 | +159.40% | 2 | Dec 19, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $147 → $145 | $103.00 | +40.78% | 7 | Dec 19, 2025 | |
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $9.36 | -35.90% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $11.71 | +70.79% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $24.36 | +31.36% | 6 | Nov 18, 2025 | |
| ENTA Enanta Pharmaceuticals | Initiates: Overweight | $17 | $13.49 | +26.02% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $33 | $19.90 | +65.83% | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $57 | $57.93 | -1.61% | 10 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $11.70 | +130.77% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $77 | $67.91 | +13.39% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.36 | +32.31% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $5.87 | +87.39% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $22.47 | +60.21% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $26.68 | -10.04% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $32.11 | +146.03% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $8.39 | +31.11% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $45.54 | -18.75% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.52 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $18.12 | +32.45% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $54.29 | +47.36% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $22.51 | +419.77% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $30.73 | +43.18% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $47.39 | -15.59% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.16 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.50 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.58 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.89 | +165.85% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $4.20 | +5,852.38% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.73 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $68.26 | -15.03% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $19.26 | -37.69% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $7.43 | +397.98% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $86.59 | -36.48% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.23 | +271.46% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $13.02 | +115.05% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $30.20 | +78.81% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.19 | +23,621.67% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $15.45 | +74.76% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $329.35 | -58.40% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $10.69 | +349.02% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.89 | +3,288.30% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $70.50 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.75 | - | 2 | Jul 21, 2017 |
Neurocrine Biosciences
Feb 17, 2026
Maintains: Overweight
Price Target: $177 → $176
Current: $128.38
Upside: +37.09%
Zai Lab
Feb 5, 2026
Maintains: Overweight
Price Target: $46 → $39
Current: $19.72
Upside: +97.77%
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $42.06
Upside: +128.25%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $37.06
Upside: +80.79%
Vor Biopharma
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $15.42
Upside: +159.40%
Nuvalent
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $103.00
Upside: +40.78%
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $9.36
Upside: -35.90%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $11.71
Upside: +70.79%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $24.36
Upside: +31.36%
Enanta Pharmaceuticals
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.49
Upside: +26.02%
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $19.90
Upside: +65.83%
Nov 12, 2025
Maintains: Overweight
Price Target: $55 → $57
Current: $57.93
Upside: -1.61%
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $11.70
Upside: +130.77%
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $67.91
Upside: +13.39%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.36
Upside: +32.31%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.87
Upside: +87.39%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $22.47
Upside: +60.21%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $26.68
Upside: -10.04%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $32.11
Upside: +146.03%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $8.39
Upside: +31.11%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $45.54
Upside: -18.75%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.52
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $18.12
Upside: +32.45%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $54.29
Upside: +47.36%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $22.51
Upside: +419.77%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $30.73
Upside: +43.18%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $47.39
Upside: -15.59%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.16
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.50
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $5.58
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.89
Upside: +165.85%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $4.20
Upside: +5,852.38%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.73
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $68.26
Upside: -15.03%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $19.26
Upside: -37.69%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $7.43
Upside: +397.98%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $86.59
Upside: -36.48%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.23
Upside: +271.46%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $13.02
Upside: +115.05%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $30.20
Upside: +78.81%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.19
Upside: +23,621.67%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $15.45
Upside: +74.76%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $329.35
Upside: -58.40%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $10.69
Upside: +349.02%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.89
Upside: +3,288.30%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $70.50
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.75
Upside: -